Literature DB >> 19337247

Prognostic indices for Budd-Chiari syndrome: valid for clinical studies but insufficient for individual management.

Pierre-Emmanuel Rautou1, Rami Moucari, Sylvie Escolano, Dominique Cazals-Hatem, Cécile Denié, Carine Chagneau-Derrode, Claire Charpignon, Victor de Lédinghen, Marieke Grenouillet-Delacre, François Habersetzer, Jean-Baptiste Nousbaum, Marie-Hélène Denninger, Dominique C Valla, Aurélie Plessier.   

Abstract

OBJECTIVES: Several prognostic indices (PIs) have been proposed for Budd-Chiari syndrome (BCS). However, patient characteristics, causal factors, and treatment outcomes have changed since these indices have been elaborated. Validation in a recent patient population and comparison of predictive accuracy between these PIs are needed.
METHODS: A database of 96 BCS patients diagnosed between 1995 and 2005 was analyzed. Cox survival models were fitted with time to liver transplantation or death, and time to invasive therapy or death, as end points. The prognostic values of known indices (Child-Pugh score, model for end-stage liver disease (MELD), Clichy, Rotterdam BCS index, New Clichy, and BCS-TIPS (transjugular intrahepatic portosystemic shunt)) at diagnosis were assessed in Cox models using the chi-square test, the Kent and O'Quigley measure of dependence, and unrestricted bootstrapping analysis. Areas under receiver operating characteristic curves (AUROCs) were built for both end points and compared.
RESULTS: All prognostic indices, except BCS-TIPS, were significant predictors of transplant-free and invasive therapy-free survival. However, only 31 and 37% of the variance in transplant-free and invasive therapy-free survival, respectively, were explained by the best performing indices. For transplant-free survival, AUROCs were < 0.70. For invasive therapy-free survival, AUROCs were < 0.80. For both end points, BCS-TIPS PI AUROCs were significantly lower than others.
CONCLUSIONS: Most PIs are valid for transplant-free survival and invasive therapy-free survival in a population of current BCS patients, and thus can be used for stratification in clinical studies. However, predictive accuracy is insufficient to be used for individual patients.

Entities:  

Mesh:

Year:  2009        PMID: 19337247     DOI: 10.1038/ajg.2009.63

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  10 in total

Review 1.  Budd-Chiari syndrome/hepatic venous outflow tract obstruction.

Authors:  Dominique-Charles Valla
Journal:  Hepatol Int       Date:  2017-07-06       Impact factor: 6.047

Review 2.  Budd-Chiari syndrome and liver transplantation.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Intractable Rare Dis Res       Date:  2015-02

3.  Presence of Ascites at Presentation is Associated With Absence of Long-Term Response Amongst Patients With Budd-Chiari Syndrome When Treated With Medical Therapy Alone: A Single Centre Real-Life Experience.

Authors:  Dhiraj Agrawal; Deepak Gupta; Rohit Nathani; Prashant Dhore; Megha Meshram; Shobna J Bhatia; Akash Shukla
Journal:  J Clin Exp Hepatol       Date:  2021-11-03

Review 4.  Budd-Chiari syndrome.

Authors:  Pieter Martens; Frederik Nevens
Journal:  United European Gastroenterol J       Date:  2015-12       Impact factor: 4.623

5.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

6.  Validation of prognostic indices in Egyptian Budd-Chiari syndrome patients: A single-center study.

Authors:  Mohammad Sakr; Sara M Abdelhakam; Soheir A Elsayed; Enas H Allam; Amir M Farid; Waleed Abdelmoaty; Azza M Hassan; Mohamed Shaker; Mohamed El-Gharib; Ahmed Eldorry
Journal:  World J Gastroenterol       Date:  2017-01-28       Impact factor: 5.742

7.  Liver and Spleen Stiffness Measurements for Assessment of Portal Hypertension Severity in Patients with Budd Chiari Syndrome.

Authors:  Elton Dajti; Federico Ravaioli; Antonio Colecchia; Giovanni Marasco; Amanda Vestito; Davide Festi
Journal:  Can J Gastroenterol Hepatol       Date:  2019-01-02

Review 8.  State of the Art, Current Perspectives, and Controversies of Budd-Chiari Syndrome: A Review.

Authors:  Paschalis Gavriilidis; Gabriele Marangoni; Jawad Ahmad; Daniel Azoulay
Journal:  J Clin Med Res       Date:  2022-04-30

9.  Percutaneous transluminal angioplasty for symptomatic hepatic vein-type Budd-Chiari syndrome: feasibility and long-term outcomes.

Authors:  Aboelyazid Elkilany; Mohamed Alwarraky; Timm Denecke; Dominik Geisel
Journal:  Sci Rep       Date:  2022-08-18       Impact factor: 4.996

Review 10.  An Update on the Management of Budd-Chiari Syndrome.

Authors:  A Sharma; S N Keshava; A Eapen; E Elias; C E Eapen
Journal:  Dig Dis Sci       Date:  2020-07-20       Impact factor: 3.199

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.